Oramed Pharmaceuticals Inc. (ORMP)
Automate Your Wheel Strategy on ORMP
With Tiblio's Option Bot, you can configure your own wheel strategy including ORMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORMP
- Rev/Share 0.0
- Book/Share 3.8028
- PB 0.5621
- Debt/Equity 0.0027
- CurrentRatio 27.0764
- ROIC -0.0501
- MktCap 87828575.0
- FreeCF/Share -0.1939
- PFCF -11.0769
- PE 19.6928
- Debt/Assets 0.0026
- DivYield 0
- ROE 0.0269
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha …
Read More
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.
Read More
About Oramed Pharmaceuticals Inc. (ORMP)
- IPO Date 2007-05-01
- Website https://www.oramed.com
- Industry Biotechnology
- CEO Mr. Nadav Kidron Esq.
- Employees 13